Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free PDSB Stock Alerts

PDS Biotechnology (PDSB) Financials

PDS Biotechnology logo
$0.77 -0.01 (-1.69%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$0.78 +0.00 (+0.14%)
As of 07/10/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for PDS Biotechnology

Annual Income Statements for PDS Biotechnology

This table shows PDS Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -32 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Consolidated Net Income / (Loss)		 -28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Net Income / (Loss) Continuing Operations		 -28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Total Pre-Tax Income 		-29 -41 -53 -3.84 -7.38 -15 -21 -42 -44 -38 -36
Total Operating Income		 -26 -40 -52 -3.65 -21 -15 -21 -42 -43 -36 -32
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 26 40 52 3.65 21 15 21 42 43 36 32
Selling, General & Admin Expense		 8.66 15 18 2.79 11 6.98 10 12 15 14 13
Research & Development Expense		 18 25 34 0.83 6.10 7.92 11 29 28 23 19
Total Other Income / (Expense), net		 -2.69 -1.15 -1.48 -0.19 14 0.06 0.01 -0.38 -1.30 -2.16 -4.12
Interest Expense		 0.82 1.20 2.18 0.19 0.03 - 0.00 1.32 4.21 4.67 5.34
Interest & Investment Income		 0.01 0.21 0.70 0.00 0.35 0.06 0.01 0.94 2.90 2.51 1.22
Income Tax Expense		 -1.11 -1.85 -2.59 0.00 -0.38 0.00 -4.52 -1.20 -1.41 -0.87 -1.17
Basic Earnings per Share		 - - - $1.15 ($1.44) ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Weighted Average Basic Shares Outstanding		 8.09M 28.86M 30.39M 3.34M 4.87M 16.75M 25.60M 28.60M 30.95M 36.45M 46.38M
Diluted Earnings per Share		 - - - $1.15 ($1.44) ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Weighted Average Diluted Shares Outstanding		 8.09M 28.86M 30.39M 3.34M 4.87M 16.75M 25.60M 28.60M 30.95M 36.45M 46.38M
Weighted Average Basic & Diluted Shares Outstanding		 8.09M 28.86M 30.39M 3.34M 4.87M 16.75M 28.45M 30.72M 36.68M 45.40M 55.82M

Quarterly Income Statements for PDS Biotechnology

This table shows PDS Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -11 -11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35
Consolidated Net Income / (Loss)		 -11 -11 -11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35
Net Income / (Loss) Continuing Operations		 -11 -11 -11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35
Total Pre-Tax Income 		-11 -11 -11 -9.20 -11 -7.95 -9.66 -9.43 -9.01 -7.56 -7.35
Total Operating Income		 -11 -10 -10 -8.68 -10 -7.36 -9.11 -7.62 -8.14 -6.67 -6.52
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 11 10 10 8.68 10 7.36 9.11 7.62 8.14 6.67 6.52
Selling, General & Admin Expense		 4.07 2.94 3.39 4.16 3.37 2.83 3.27 3.41 3.56 2.27 3.06
Research & Development Expense		 6.45 7.47 6.70 4.53 6.80 4.53 5.83 4.21 4.58 4.41 3.46
Total Other Income / (Expense), net		 -0.33 -0.49 -0.51 -0.51 -0.55 -0.59 -0.55 -1.81 -0.87 -0.89 -0.83
Interest Expense		 1.07 1.17 1.17 1.19 1.21 1.10 0.93 2.14 1.15 1.11 1.01
Interest & Investment Income		 0.74 0.68 0.67 0.68 0.67 0.50 0.38 0.33 0.28 0.22 0.19
Income Tax Expense		 0.00 - 0.00 -0.87 0.00 - -1.17 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.35) ($0.35) ($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13)
Weighted Average Basic Shares Outstanding		 30.91M 30.95M 34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M
Diluted Earnings per Share		 ($0.35) ($0.35) ($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13)
Weighted Average Diluted Shares Outstanding		 30.91M 30.95M 34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M
Weighted Average Basic & Diluted Shares Outstanding		 31.11M 36.68M 36.68M 36.82M 37.41M 45.40M 45.71M 46.63M 48.98M 55.82M 55.82M

Annual Cash Flow Statements for PDS Biotechnology

This table details how cash moves in and out of PDS Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 116 -24 -18 -0.14 12 17 36 8.58 -17 -15 -15
Net Cash From Operating Activities		 -22 -32 -41 -1.57 -18 -13 -12 -26 -34 -35 -28
Net Cash From Continuing Operating Activities		 -22 -32 -41 -1.64 -18 -13 -12 -26 -34 -35 -28
Net Income / (Loss) Continuing Operations		 -28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Consolidated Net Income / (Loss)		 -28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Depreciation Expense		 0.05 0.10 0.18 0.07 0.10 0.02 0.01 0.00 0.02 0.02 0.02
Amortization Expense		 0.20 0.17 0.14 - - - 0.00 0.23 0.69 1.20 1.59
Non-Cash Adjustments To Reconcile Net Income		 4.82 5.58 6.76 1.05 -6.19 0.49 4.18 10 8.40 7.12 5.51
Changes in Operating Assets and Liabilities, net		 1.26 0.78 3.14 1.15 -4.99 1.17 0.25 4.90 0.04 -5.75 -0.38
Net Cash From Investing Activities		 -1.31 -0.69 -0.19 0.00 29 0.00 0.00 0.00 0.00 -0.03 0.00
Net Cash From Continuing Investing Activities		 -1.31 -0.69 -0.19 0.00 29 0.00 0.00 0.00 0.00 -0.03 0.00
Purchase of Property, Plant & Equipment		 -1.31 -0.69 -0.19 - - - - - 0.00 -0.03 0.00
Net Cash From Financing Activities		 140 9.08 23 1.50 0.75 30 49 34 16 20 13
Net Cash From Continuing Financing Activities		 140 9.08 23 1.50 0.75 30 49 34 16 20 13
Repayment of Debt		 -0.53 -1.71 0.00 -0.02 - - 0.00 -0.45 0.00 -3.13 -26
Issuance of Debt		 55 11 5.00 - - - 0.00 25 - 0.00 19
Issuance of Common Equity		 86 0.00 17 1.28 0.75 30 49 9.86 16 23 19
Other Financing Activities, net		 0.00 0.31 0.17 0.23 0.00 0.07 0.34 -0.12 0.25 0.72 -0.06
Cash Interest Paid		 0.56 0.79 1.64 0.00 - - 0.00 0.85 3.54 3.56 2.92

Quarterly Cash Flow Statements for PDS Biotechnology

This table details how cash moves in and out of PDS Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -6.37 2.31 10 -8.90 -7.98 -8.06 -1.71 -8.11 -5.67 0.51 -5.05
Net Cash From Operating Activities		 -7.18 -8.46 -9.94 -8.86 -8.00 -8.23 -9.03 -9.10 -5.92 -3.70 -4.37
Net Cash From Continuing Operating Activities		 -7.18 -8.62 -9.94 -8.86 -8.00 -8.23 -9.03 -9.10 -5.92 -3.70 -4.37
Net Income / (Loss) Continuing Operations		 -11 -11 -11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35
Consolidated Net Income / (Loss)		 -11 -11 -11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35
Depreciation Expense		 -0.02 0.00 0.00 0.02 0.02 0.01 0.02 -0.00 0.01 0.01 0.02
Amortization Expense		 0.16 0.30 0.27 0.28 0.31 0.31 0.27 1.11 -0.28 0.48 0.45
Non-Cash Adjustments To Reconcile Net Income		 1.90 1.57 1.64 2.05 1.78 1.64 1.46 0.47 1.98 1.61 1.16
Changes in Operating Assets and Liabilities, net		 1.63 0.40 -1.25 -2.89 0.63 -2.24 -2.29 -1.24 1.39 1.76 1.36
Net Cash From Investing Activities		 - - 0.00 -0.03 -0.00 - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 -0.03 -0.00 - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.80 11 20 -0.01 0.02 0.17 7.32 1.00 0.24 4.22 -0.68
Net Cash From Continuing Financing Activities		 0.80 11 20 -0.01 0.02 0.17 7.32 1.00 0.24 4.22 -0.68
Repayment of Debt		 - - 0.00 - - - -3.13 -20 -1.00 -1.85 -1.50
Issuance of Debt		 - - - - - - 1.01 - 0.00 -0.03 0.00
Issuance of Common Equity		 0.82 10 19 - -0.07 3.17 9.45 1.46 1.26 7.13 0.83
Other Financing Activities, net		 -0.01 0.29 0.52 -0.01 0.08 0.13 -0.01 -0.02 -0.02 -1.03 -0.01
Cash Interest Paid		 0.66 0.91 1.17 1.19 0.36 0.84 0.69 0.89 0.70 0.64 0.56

Annual Balance Sheets for PDS Biotechnology

This table presents PDS Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 134 111 93 0.16 14 31 67 77 59 45 30
Total Current Assets		 131 107 89 0.12 14 30 67 76 59 45 28
Cash & Equivalents		 130 106 88 0.10 12 29 65 74 57 42 27
Prepaid Expenses		 1.08 0.95 0.99 0.02 2.31 1.50 1.60 2.66 2.49 3.36 1.54
Plant, Property, & Equipment, net		 2.77 3.42 3.42 0.03 0.02 0.01 0.00 0.00 0.13 0.14 0.12
Total Noncurrent Assets		 0.06 0.14 0.14 0.01 0.00 0.55 0.36 0.53 0.20 0.16 2.12
Noncurrent Note & Lease Receivables		 - - - - - - 0.00 0.37 0.20 0.16 0.12
Other Noncurrent Operating Assets		 0.06 0.14 0.14 0.01 0.00 0.55 0.36 0.15 - 0.00 2.00
Total Liabilities & Shareholders' Equity		 134 111 93 0.16 14 31 67 77 59 45 30
Total Liabilities		 12 22 30 2.23 2.79 3.76 3.99 33 33 26 21
Total Current Liabilities		 8.59 6.68 13 1.91 2.79 3.27 3.76 9.82 14 17 9.48
Short-Term Debt		 2.27 0.00 3.08 - - - - 0.00 4.17 13 5.13
Accounts Payable		 2.58 3.47 4.37 1.31 1.20 1.42 1.31 1.22 6.98 1.68 3.57
Accrued Expenses		 3.73 3.21 5.42 0.60 1.10 1.74 2.19 8.31 2.42 2.84 0.74
Other Current Liabilities		 - - 0.00 0.00 0.50 0.12 0.26 0.29 0.06 0.06 0.04
Total Noncurrent Liabilities		 3.03 15 17 0.32 0.00 0.49 0.23 23 20 9.27 12
Long-Term Debt		 3.03 15 17 0.03 - - 0.00 23 20 9.20 12
Capital Lease Obligations		 - - - - - - 0.00 0.16 0.12 0.06 0.03
Commitments & Contingencies		 - - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 122 89 62 -2.07 12 27 63 44 26 19 9.25
Total Preferred & Common Equity		 122 89 62 -2.07 12 27 63 44 26 19 9.25
Total Common Equity		 122 89 62 -2.07 12 27 63 44 26 19 9.25
Common Stock		 185 190 214 20 41 71 124 146 171 201 226
Retained Earnings		 -62 -101 -152 -22 -29 -44 -61 -102 -145 -182 -217

Quarterly Balance Sheets for PDS Biotechnology

This table presents PDS Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 57 69 60 52 47 40 35 25
Total Current Assets		 57 69 60 52 42 34 28 23
Cash & Equivalents		 54 67 58 50 40 32 26 22
Prepaid Expenses		 2.59 2.05 2.43 2.38 2.49 1.77 1.69 1.23
Plant, Property, & Equipment, net		 0.14 0.13 0.15 0.15 0.14 0.13 0.13 0.11
Total Noncurrent Assets		 0.21 0.19 0.18 0.17 4.42 6.70 6.69 1.66
Noncurrent Note & Lease Receivables		 0.21 0.19 0.18 0.17 0.15 0.14 0.13 0.11
Other Noncurrent Operating Assets		 0.00 - - - 4.27 6.55 6.55 1.55
Total Liabilities & Shareholders' Equity		 57 69 60 52 47 40 35 25
Total Liabilities		 33 32 30 30 25 25 25 21
Total Current Liabilities		 9.15 15 16 18 18 12 13 10
Short-Term Debt		 0.00 7.29 10 13 13 5.50 6.00 5.21
Accounts Payable		 5.37 6.00 3.25 1.30 2.86 4.50 5.18 3.65
Accrued Expenses		 3.73 1.71 1.95 4.48 2.85 1.48 2.10 1.26
Other Current Liabilities		 0.05 0.06 0.06 0.06 0.06 0.05 0.04 0.03
Total Noncurrent Liabilities		 24 17 14 12 6.40 13 12 11
Long-Term Debt		 23 17 14 12 6.35 13 12 11
Capital Lease Obligations		 0.14 0.11 0.09 0.08 0.05 0.04 0.03 0.02
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 24 37 31 22 22 16 9.45 3.89
Total Preferred & Common Equity		 24 37 31 22 22 16 9.45 3.89
Total Common Equity		 24 37 31 22 22 16 9.45 3.89
Common Stock		 158 192 194 196 213 216 218 228
Retained Earnings		 -134 -155 -163 -174 -191 -200 -209 -224

Annual Metrics And Ratios for PDS Biotechnology

This table displays calculated financial ratios and metrics derived from PDS Biotechnology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 28,810,845.00 28,917,419.00 30,859,200.00 31,328,128.00 5,778,850.00 22,261,619.00 28,435,067.00 28,508,688.00 31,107,763.00 - 48,980,307.00
DEI Adjusted Shares Outstanding		 1,440,542.00 1,445,871.00 1,542,960.00 1,566,406.00 5,778,850.00 22,261,619.00 28,435,067.00 28,508,688.00 31,107,763.00 - 48,980,307.00
DEI Earnings Per Adjusted Shares Outstanding		 -22.52 -26.85 -32.96 -2.45 -1.21 -0.67 -0.60 -1.43 -1.38 - -0.70
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -124.20% -40.11% -31.04% 93.07% -112.46% -95.84% -43.98% -93.34% -2.16% 17.08% 14.74%
EBIT Growth		 -125.02% -39.81% -30.98% 92.98% -111.13% -93.54% -43.87% -94.37% -3.29% 15.62% 13.15%
NOPAT Growth		 -100.84% -49.11% -31.52% 92.98% -476.89% 29.15% -43.87% -94.37% -3.29% 15.62% 13.15%
Net Income Growth		 -130.13% -38.26% -31.01% 92.46% -82.42% -112.15% -13.95% -141.48% -5.11% 12.42% 8.28%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -225.22% 38.19% 25.84% -116.67% 2.80% 25.90% 28.16%
Operating Cash Flow Growth		 -123.90% -47.98% -26.43% 96.14% -1,051.49% 27.25% 5.04% -105.91% -30.83% -4.14% 20.78%
Free Cash Flow Firm Growth		 -159.63% -52.36% -19.36% 83.04% -190.25% 43.99% -59.87% -67.31% -22.64% -3.35% 27.98%
Invested Capital Growth		 -10.72% 10.19% -141.47% 59.15% 78.32% -268.51% -18.84% -226.41% -0.01% 86.16% 37.84%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -6.15% -11.17% 80.20% -65.03% 11.59% -12.00% -42.59% 16.88% 8.00% 2.80%
EBIT Q/Q Growth		 0.00% -5.96% -11.08% 79.89% -62.18% 11.59% -11.98% -42.85% 16.35% 7.74% 2.13%
NOPAT Q/Q Growth		 0.00% -5.52% -11.08% 79.90% -26.06% 11.59% -11.98% -42.85% 16.35% 7.74% 2.13%
Net Income Q/Q Growth		 0.00% -4.18% -9.44% 75.90% -50.82% 1.01% -15.68% -45.72% 16.10% 7.26% 1.12%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 75.90% -63.64% -12.66% -29.41% -38.84% 17.75% 11.97% 9.76%
Operating Cash Flow Q/Q Growth		 -21.83% 2.24% -8.52% 85.04% -40.42% 6.34% 1.01% -13.35% -2.84% 0.63% 14.04%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -7.82% 38.46% -4.55% 21.49% -9.29% -16.86% 3.08% -1.65% 16.56%
Invested Capital Q/Q Growth		 0.00% -372.60% -126.22% 63.30% 74.56% 11.04% -7.69% -417.08% -6.70% 70.77% -148.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 96.21% 95.46% 95.16% 100.00% 94.83% 100.00% 78.93% 97.15% 96.83% 97.74% 96.72%
Interest Burden Percent		 102.85% 102.50% 102.85% 105.19% 95.85% 99.63% 99.98% 100.92% 103.03% 105.94% 113.07%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -42.73% -36.67% -67.08% -12.72% -145.33% -76.48% -37.46% -76.21% -122.46% -166.65% -244.16%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -30.77% -36.67% -67.08% -12.72% -145.33% -76.48% -37.46% -76.21% -122.46% -166.65% -244.16%
Return on Equity Simple (ROE_SIMPLE)		 -22.93% -43.48% -81.54% 185.68% -59.83% -54.73% -26.77% -92.85% -164.33% -197.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -28 -36 -2.55 -15 -10 -15 -29 -30 -25 -22
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -14.01% -10.32% -18.21% -3.79% 126.28% -21.54% -4.06% -20.17% -30.72% -46.26% -83.47%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -60.35% -62.36% -84.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -28 -40 -52 -3.65 -7.70 -15 -21 -42 -43 -36 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -39 -52 -3.58 -7.60 -15 -21 -41 -42 -35 -30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.94 4.05 4.64 0.00 1.31 1.76 3.64 8.55 5.92 3.21 4.08
Price to Tangible Book Value (P/TBV)		 2.94 4.05 4.64 0.00 1.31 1.76 3.64 8.55 5.92 3.21 4.08
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.04 0.17 0.33 -0.01 0.00 0.00 0.00 0.53 0.91 1.15 1.83
Long-Term Debt to Equity		 0.02 0.17 0.28 -0.01 0.00 0.00 0.00 0.53 0.75 0.49 1.27
Financial Leverage		 -1.04 -1.02 -1.05 -1.12 -1.27 -1.06 -1.04 -1.08 -1.19 -1.17 -1.05
Leverage Ratio		 1.15 1.16 1.34 1.54 1.52 1.17 1.09 1.35 1.94 2.32 2.68
Compound Leverage Factor		 1.18 1.19 1.38 1.62 1.46 1.16 1.09 1.36 2.00 2.46 3.04
Debt to Total Capital		 4.15% 14.35% 24.70% -1.47% 0.00% 0.00% 0.00% 34.51% 47.66% 53.39% 64.61%
Short-Term Debt to Total Capital		 1.78% 0.00% 3.71% 0.00% 0.00% 0.00% 0.00% 0.00% 8.35% 30.66% 19.63%
Long-Term Debt to Total Capital		 2.37% 14.35% 20.99% -1.47% 0.00% 0.00% 0.00% 34.51% 39.32% 22.73% 44.98%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.85% 85.65% 75.30% 101.47% 100.00% 100.00% 100.00% 65.49% 52.34% 46.61% 35.39%
Debt to EBITDA		 -0.19 -0.38 -0.40 -0.01 0.00 0.00 0.00 -0.56 -0.56 -0.62 -0.56
Net Debt to EBITDA		 4.44 2.32 1.31 0.02 0.00 0.00 0.00 1.22 0.77 0.57 0.33
Long-Term Debt to EBITDA		 -0.11 -0.38 -0.34 -0.01 0.00 0.00 0.00 -0.56 -0.46 -0.26 -0.39
Debt to NOPAT		 -0.29 -0.54 -0.56 -0.01 0.00 0.00 0.00 -0.79 -0.79 -0.86 -0.76
Net Debt to NOPAT		 6.73 3.31 1.86 0.03 0.00 0.00 0.00 1.74 1.09 0.78 0.44
Long-Term Debt to NOPAT		 -0.16 -0.54 -0.48 -0.01 0.00 0.00 0.00 -0.79 -0.65 -0.36 -0.53
Altman Z-Score		 18.35 8.66 2.57 -270.33 -0.29 5.08 33.47 4.25 -2.09 -6.14 -11.55
Noncontrolling Interest Sharing Ratio		 27.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.28 16.06 6.92 0.06 5.18 9.28 17.80 7.79 4.33 2.64 2.98
Quick Ratio		 15.16 15.92 6.84 0.05 4.35 8.82 17.37 7.52 4.15 2.44 2.82
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -28 -33 -5.65 -16 -9.19 -15 -25 -30 -31 -22
Operating Cash Flow to CapEx		 -1,666.76% -4,687.41% -21,564.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -120,793.87% 0.00%
Free Cash Flow to Firm to Interest Expense		 -22.43 -23.18 -15.28 -29.83 -488.69 0.00 0.00 -18.66 -7.16 -6.66 -4.20
Operating Cash Flow to Interest Expense		 -26.64 -26.74 -18.67 -8.29 -538.56 0.00 0.00 -19.53 -8.00 -7.50 -5.20
Operating Cash Flow Less CapEx to Interest Expense		 -28.24 -27.31 -18.75 -8.29 -530.36 0.00 0.00 -19.53 -8.00 -7.50 -5.20
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.42 -2.17 -5.24 -2.14 -0.46 -1.71 -2.03 -6.63 -6.63 -0.92 -0.57
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.23 0.25 -3.07 3.10 1.68 -1.25 -0.32 -4.60 -0.00 5.72 0.35
Enterprise Value (EV)		 235 270 222 9.98 3.15 19 165 326 122 41 28
Market Capitalization		 360 361 289 10 15 48 230 376 155 61 38
Book Value per Share		 $4.25 $3.09 $2.02 ($0.07) $2.02 $1.22 $2.22 $1.54 $0.84 $0.51 $0.19
Tangible Book Value per Share		 $4.25 $3.09 $2.02 ($0.07) $2.02 $1.22 $2.22 $1.54 $0.84 $0.51 $0.19
Total Capital		 128 104 83 -2.04 12 27 63 67 50 41 26
Total Debt		 5.30 15 20 0.03 0.00 0.00 0.00 23 24 22 17
Total Long-Term Debt		 3.03 15 17 0.03 0.00 0.00 0.00 23 20 9.27 12
Net Debt		 -125 -91 -68 -0.07 -12 -29 -65 -51 -33 -20 -9.82
Capital Expenditures (CapEx)		 1.31 0.69 0.19 0.00 -0.28 0.00 0.00 0.00 0.00 0.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.24 -5.73 -8.80 -1.89 -0.49 -1.77 -2.16 -7.16 -6.97 -1.22 -2.81
Debt-free Net Working Capital (DFNWC)		 125 101 79 -1.79 12 27 63 67 50 40 24
Net Working Capital (NWC)		 123 101 76 -1.79 12 27 63 67 45 28 19
Net Nonoperating Expense (NNE)		 9.53 11 14 1.28 -7.73 4.42 1.91 12 13 12 12
Net Nonoperating Obligations (NNO)		 -125 -91 -68 -0.07 -12 -29 -65 -51 -33 -20 -9.82
Total Depreciation and Amortization (D&A)		 0.25 0.27 0.32 0.07 0.10 0.02 0.01 0.23 0.71 1.22 1.61
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $1.44 ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Adjusted Weighted Average Basic Shares Outstanding		 1.44M 1.45M 1.54M 1.58M 15.29M 22.26M 25.60M 28.60M 30.95M 36.45M 46.38M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $1.44 ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Adjusted Weighted Average Diluted Shares Outstanding		 1.44M 1.45M 1.54M 1.58M 15.29M 22.26M 25.60M 28.60M 30.95M 36.45M 46.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $1.44 ($0.89) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 404.40K 1.44M 1.52M 1.56M 4.87M 16.75M 28.45M 30.72M 36.68M 45.40M 55.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -28 -36 -2.55 -13 -10 -15 -29 -30 -25 -22
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -34.76 -32.96 -23.84 -19.26 -229.45 0.00 0.00 -31.65 -10.23 -7.77 -5.91
NOPAT to Interest Expense		 -22.72 -22.98 -16.69 -13.48 -438.76 0.00 0.00 -22.16 -7.16 -5.44 -4.14
EBIT Less CapEx to Interest Expense		 -36.36 -33.53 -23.92 -19.26 -221.25 0.00 0.00 -31.65 -10.23 -7.78 -5.91
NOPAT Less CapEx to Interest Expense		 -24.32 -23.55 -16.77 -13.48 -430.56 0.00 0.00 -22.16 -7.16 -5.45 -4.14
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -5.00% -1.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PDS Biotechnology

This table displays calculated financial ratios and metrics derived from PDS Biotechnology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 30,868,188.00 31,107,763.00 36,679,275.00 36,679,275.00 36,819,810.00 - 45,395,851.00 45,710,000.00 46,633,362.00 48,980,307.00 55,815,653.00
DEI Adjusted Shares Outstanding		 30,868,188.00 31,107,763.00 36,679,275.00 36,679,275.00 36,819,810.00 - 45,395,851.00 45,710,000.00 46,633,362.00 48,980,307.00 55,815,653.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.35 -0.35 -0.29 -0.23 -0.29 - -0.19 -0.21 -0.19 -0.15 -0.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -44.75% 45.97% -5.78% 33.37% 5.00% 30.24% 10.23% 22.23% 14.66% 12.24% 31.31%
EBIT Growth		 -44.52% 44.71% -7.17% 31.60% 3.24% 29.27% 9.82% 12.22% 20.03% 9.32% 28.39%
NOPAT Growth		 -44.52% 44.71% -7.17% 31.60% 3.24% 29.27% 9.82% 12.22% 20.03% 9.32% 28.39%
Net Income Growth		 -46.13% 43.05% -9.77% 27.80% 1.13% 27.03% 19.94% -13.28% 16.01% 4.90% 13.43%
EPS Growth		 -34.62% 46.15% 6.25% 37.84% 17.14% 40.00% 30.00% 8.70% 34.48% 38.10% 38.10%
Operating Cash Flow Growth		 -21.77% -12.33% 24.65% -83.99% -11.48% 2.63% 9.12% -2.75% 26.05% 55.04% 51.60%
Free Cash Flow Firm Growth		 57.38% 15.04% 70.78% -44.79% -319.96% -49.20% -412.39% -25.37% 1.81% 53.81% 89.72%
Invested Capital Growth		 -384.66% -0.01% -513.44% 47.07% 49.48% 86.16% 123.79% 203.01% 137.50% 37.84% -250.84%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 17.45% 2.65% 2.77% 14.73% -17.70% 28.37% -25.12% 26.13% -29.16% 26.48% 2.07%
EBIT Q/Q Growth		 17.14% 1.07% 2.97% 14.00% -17.21% 27.69% -23.71% 16.28% -6.78% 18.00% 2.30%
NOPAT Q/Q Growth		 17.14% 1.07% 2.97% 14.00% -17.21% 27.69% -23.71% 16.28% -6.78% 18.00% 2.30%
Net Income Q/Q Growth		 5.94% -0.45% 2.70% 21.46% -28.80% 25.86% -6.75% -11.13% 4.50% 16.06% 2.83%
EPS Q/Q Growth		 5.41% 0.00% 14.29% 23.33% -26.09% 27.59% 0.00% 0.00% 9.52% 31.58% 0.00%
Operating Cash Flow Q/Q Growth		 -49.05% -17.85% -17.51% 10.87% 9.69% -2.93% -9.69% -0.76% 35.00% 37.41% -18.07%
Free Cash Flow Firm Q/Q Growth		 57.62% -199.86% 65.01% -225.61% -22.94% -6.53% -20.16% 20.33% 3.72% 49.89% 73.25%
Invested Capital Q/Q Growth		 -31.86% -6.70% 18.60% 53.78% -25.84% 70.77% 239.91% 100.16% -54.20% -148.46% -239.50%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 90.55% 100.00% 100.00% 87.89% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.13% 104.72% 105.01% 105.90% 105.38% 108.04% 106.07% 123.75% 110.68% 113.31% 112.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -143.08% -122.46% -112.25% -128.40% -174.49% -166.65% -119.22% -156.16% -221.81% -244.16% -254.09%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,445.66% -1,130.05% -2,282.38% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -143.08% -122.46% -112.25% -128.40% -174.49% -166.65% -119.22% -156.16% -221.81% -244.16% -254.09%
Return on Equity Simple (ROE_SIMPLE)		 -209.04% 0.00% -118.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.36 -7.28 -7.07 -6.08 -7.13 -5.15 -6.37 -5.34 -5.70 -4.67 -4.56
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.82% -8.67% -8.37% -6.37% -12.90% -10.63% -6.64% -17.51% -19.82% -19.44% -20.70%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.59% -11.54% -11.01% -15.29% -12.64% -15.45% -15.49% -20.81% -17.87% -23.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -10 -10 -8.68 -10 -7.36 -9.11 -7.62 -8.14 -6.67 -6.52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -10 -9.82 -8.38 -9.86 -7.05 -8.82 -6.51 -8.41 -6.19 -6.06
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.37 5.92 3.91 3.48 6.39 3.21 2.42 3.81 4.98 4.08 8.67
Price to Tangible Book Value (P/TBV)		 6.37 5.92 3.91 3.48 6.39 3.21 2.42 3.81 4.98 4.08 8.67
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 25.65 18.44 32.97 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.96 0.91 0.65 0.79 1.12 1.15 0.85 1.16 1.90 1.83 4.07
Long-Term Debt to Equity		 0.96 0.75 0.45 0.45 0.55 0.49 0.29 0.81 1.26 1.27 2.73
Financial Leverage		 -1.10 -1.19 -1.08 -1.11 -1.20 -1.17 -1.07 -1.00 -1.06 -1.05 -1.02
Leverage Ratio		 1.85 1.94 1.76 1.96 2.36 2.32 1.95 2.15 2.77 2.68 2.73
Compound Leverage Factor		 1.90 2.04 1.85 2.08 2.49 2.51 2.07 2.67 3.07 3.04 3.08
Debt to Total Capital		 49.03% 47.66% 39.28% 44.03% 52.80% 53.39% 45.81% 53.67% 65.47% 64.61% 80.26%
Short-Term Debt to Total Capital		 0.00% 8.35% 11.91% 18.86% 26.82% 30.66% 30.29% 15.97% 21.92% 19.63% 26.40%
Long-Term Debt to Total Capital		 49.03% 39.32% 27.37% 25.17% 25.98% 22.73% 15.51% 37.70% 43.55% 44.98% 53.86%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 50.97% 52.34% 60.72% 55.97% 47.20% 46.61% 54.19% 46.33% 34.53% 35.39% 19.74%
Debt to EBITDA		 -0.46 -0.56 -0.56 -0.63 -0.64 -0.62 -0.55 -0.57 -0.58 -0.56 -0.58
Net Debt to EBITDA		 0.60 0.77 0.99 0.86 0.66 0.57 0.62 0.42 0.27 0.33 0.21
Long-Term Debt to EBITDA		 -0.46 -0.46 -0.39 -0.36 -0.32 -0.26 -0.19 -0.40 -0.39 -0.39 -0.39
Debt to NOPAT		 -0.65 -0.79 -0.79 -0.87 -0.89 -0.86 -0.76 -0.77 -0.79 -0.76 -0.78
Net Debt to NOPAT		 0.85 1.09 1.39 1.20 0.91 0.78 0.85 0.56 0.37 0.44 0.29
Long-Term Debt to NOPAT		 -0.65 -0.65 -0.55 -0.50 -0.44 -0.36 -0.26 -0.54 -0.53 -0.53 -0.52
Altman Z-Score		 -0.02 -0.28 0.04 -1.19 -1.74 -4.03 -4.38 -5.40 -7.58 -8.86 -11.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.21 4.33 4.56 3.84 2.84 2.64 2.33 2.92 2.09 2.98 2.26
Quick Ratio		 5.93 4.15 4.42 3.68 2.71 2.44 2.19 2.76 1.97 2.82 2.13
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.43 -7.28 -2.55 -8.30 -10 -11 -13 -10 -10 -5.02 -1.34
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -799,968,700.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -2.27 -6.20 -2.17 -6.99 -8.40 -9.92 -14.03 -4.85 -8.71 -4.51 -1.32
Operating Cash Flow to Interest Expense		 -6.71 -7.20 -8.46 -7.46 -6.59 -7.52 -9.70 -4.24 -5.14 -3.33 -4.31
Operating Cash Flow Less CapEx to Interest Expense		 -6.71 -7.20 -8.46 -7.46 -6.59 -7.52 -9.70 -4.24 -5.14 -3.33 -4.31
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.22 -6.63 -5.40 -2.50 -3.14 -0.92 1.28 2.57 1.18 -0.57 -1.94
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.93 -0.00 -4.52 2.22 3.08 5.72 6.68 5.07 4.32 0.35 -3.22
Enterprise Value (EV)		 125 122 103 74 116 41 33 47 39 28 28
Market Capitalization		 156 155 145 107 141 61 54 61 47 38 34
Book Value per Share		 $0.79 $0.84 $1.01 $0.84 $0.60 $0.51 $0.49 $0.35 $0.20 $0.19 $0.07
Tangible Book Value per Share		 $0.79 $0.84 $1.01 $0.84 $0.60 $0.51 $0.49 $0.35 $0.20 $0.19 $0.07
Total Capital		 48 50 61 55 47 41 41 34 27 26 20
Total Debt		 24 24 24 24 25 22 19 18 18 17 16
Total Long-Term Debt		 24 20 17 14 12 9.27 6.40 13 12 12 11
Net Debt		 -31 -33 -43 -33 -25 -20 -21 -13 -8.28 -9.82 -5.83
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.57 -6.97 -5.72 -2.83 -3.46 -1.22 -3.28 -4.26 -5.64 -2.81 -3.71
Debt-free Net Working Capital (DFNWC)		 48 50 61 55 46 40 37 28 21 24 18
Net Working Capital (NWC)		 48 45 54 44 34 28 24 22 15 19 13
Net Nonoperating Expense (NNE)		 3.49 3.61 3.54 2.25 3.60 2.80 2.11 4.10 3.31 2.89 2.78
Net Nonoperating Obligations (NNO)		 -31 -33 -43 -33 -25 -20 -21 -13 -8.28 -9.82 -5.83
Total Depreciation and Amortization (D&A)		 0.14 0.30 0.27 0.31 0.32 0.31 0.29 1.11 -0.27 0.49 0.46
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.35) ($0.35) ($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 30.91M 30.95M 34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M
Adjusted Diluted Earnings per Share		 ($0.35) ($0.35) ($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 30.91M 30.95M 34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.11M 36.68M 36.68M 36.82M 37.41M 45.40M 45.71M 46.63M 48.98M 55.82M 55.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.36 -7.28 -7.07 -6.08 -7.13 -5.15 -6.37 -5.34 -5.70 -4.67 -4.56
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -9.84 -8.86 -8.60 -7.31 -8.38 -6.72 -9.78 -3.55 -7.08 -6.00 -6.43
NOPAT to Interest Expense		 -6.89 -6.20 -6.02 -5.12 -5.87 -4.70 -6.85 -2.49 -4.95 -4.20 -4.50
EBIT Less CapEx to Interest Expense		 -9.84 -8.86 -8.60 -7.31 -8.38 -6.72 -9.78 -3.55 -7.08 -6.00 -6.43
NOPAT Less CapEx to Interest Expense		 -6.89 -6.20 -6.02 -5.12 -5.87 -4.70 -6.85 -2.49 -4.95 -4.20 -4.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

PDS Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PDS Biotechnology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

PDS Biotechnology's net income appears to be on an upward trend, with a most recent value of -$34.50 million in 2025, rising from -$28.08 million in 2015. The previous period was -$37.61 million in 2024. Check out PDS Biotechnology's forecast to explore projected trends and price targets.

PDS Biotechnology's total operating income in 2025 was -$31.54 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $31.54 million

Over the last 10 years, PDS Biotechnology's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

PDS Biotechnology's total liabilities were at $21.24 million at the end of 2025, a 19.4% decrease from 2024, and a 82.9% increase since 2015.

In the past 10 years, PDS Biotechnology's cash and equivalents has ranged from $103.70 thousand in 2018 to $130.19 million in 2015, and is currently $26.71 million as of their latest financial filing in 2025.

Over the last 10 years, PDS Biotechnology's book value per share changed from 4.25 in 2015 to 0.19 in 2025, a change of -95.6%.


Related Companies

Financial statements for NASDAQ:PDSB last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel